Predictive factors for progression‐free survival in non‐small cell lung cancer patients receiving nivolumab based on performance status

BACKGROUND: Nivolumab has promising efficacy for the treatment of non‐small cell lung cancer (NSCLC). Various predictive factors for nivolumab response in those with NSCLC have been reported, including performance status (PS). The objective of this retrospective study was to determine the predictive...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Cancer Med
Main Authors: Adachi, Yuichi, Tamiya, Akihiro, Taniguchi, Yoshihiko, Enomoto, Takatoshi, Azuma, Kouji, Kouno, Shunichi, Inagaki, Yuji, Saijo, Nobuhiko, Okishio, Kyoichi, Atagi, Shinji
פורמט: Artigo
שפה:Inglês
יצא לאור: John Wiley and Sons Inc. 2019
נושאים:
Clinical Cancer Research
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC7013052/
https://ncbi.nlm.nih.gov/pubmed/31880861
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2807
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים